Imaging and PSA assessment in nmCRPC patients and the treatment consequences
|Organiser||European School of Urology|
|Duration||Approx. 60 – 90 minutes|
Three pivotal trials, Prosper, Spartan and Aramis, have shown improved cancer control when treating patients with nmCRPC and low PSA doubling time. The definition of the non-metastatic stage is much depending on the sensitivity of the imaging test, rendering the non-metastatic stage as selection criteria weak. In this context, PSA gains a major role as selection criteria for treatment. On the other hand, in CRPC PSA has limitations in treatment monitoring and imaging might be a more reliable tool to decide when treatment needs to be changed.
This webinar sheds light into the difficulties encountered with PSA and imaging when treating nmCRPC patients.
Contact our organiser
European School of Urology